Supernus Pharmaceuticals FKA Sage Therapeutics

A clinical-stage biopharmaceutical company.

Based in MA

🤖

AI Overview

With $1.4M in lobbying spend across 28 quarterly filings, Supernus Pharmaceuticals FKA Sage Therapeutics is a significant lobbying presence. Their lobbying covers 2 issue areas. Active from 2018 to 2025.

$1.4M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$180K
2019	$200K
2020	$150K
2021	$150K
2022	$150K
2023	$200K
2024	$200K
2025	$150K

Issues Lobbied

Health Issues Medicare/Medicaid

Lobbying Firms

W Strategies, LLC

Lobbyists

Darren Willcox

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid

Education and awareness of mental health issues.

Education and awareness of mental health issues especially as it relates to postpartum depression.

Regulatory and legislative proposals in the Administrations Blueprint.

Maternal health demonstration project at CMMI.

H.R.3: Lower Drug Costs Now Act.

H.R.19: Lower Costs, More Cures Act of 2019.

Education and awareness of mental health issues especially as it relates to access for postpartum depression treatment.

H.R.4996: Helping MOMS Act of 2020.

H.R.133: Consolidated Appropriations Act, 2021.

Education and awareness of mental health issues especially as it relates to access for postpartum depression treatment.

H.R.1319: American Rescue Plan Act of 2021.

Education and awareness of mental health issues especially as it relates to access for postpartum depression treatment. Issues related to telehealth in the mental health space.

Showing 8 of 10 unique descriptions from filings.